Clay Siegall founds Seattle Genetics, takes target therapies to new heights

One of the most important developments over the last 20 years in the cancer research industry has been in the area of targeted cancer therapies. Many new drugs began coming on the scene in the early 1990s that showed huge promise in the ability to administer highly effective anti-cancer treatments without the terrible side effects that had normally been associated with chemotherapy regimens.

Of all the new targeted cancer therapies that have been produced over the last 20 years, the most important could arguably be the category known as antibody drug conjugates. Created by Clay Siegall, a senior researcher with Bristol-Myers Squibb who would later go on to found Seattle Genetics, one of the most important biotech startups of the last 20 years, antibody drug conjugates have proven to be one of the most effective cancer treatments ever devised.

This exciting new class of drugs is now being used to treat a variety of specific types of cancers. In cancer types for which it has been approved, the company’s first drug, ADCetris, has proven to be enormously promising, almost totally eliminating the side effects of that would normally be associated with chemotherapy and allow for vastly higher and more effective dosages to be safely administered to patients suffering from the diseases for which the drug has been approved.

As both the founder and CEO of Seattle Genetics, Dr. Clay Siegall has been instrumental in the company’s rise to success, personally overseeing the creation of ADCetris as well as other antibody drug conjugates. Under Dr. Siegall’s leadership, the company has created a robust pipeline of new drugs being researched and developed. Currently, the company has more than 15 drugs in its development pipeline and dozens more that are currently being research in the beginning stages.

In addition to that, Seattle Genetics has been able to create a vast portfolio of intellectual property, which it is able to lease out to other companies in order that they make create their own antibody drug conjugate drugs.

The most important contribution that Dr. Siegall has made to the cancer research field has been the real lives that have been saved through the use of antibody drug conjugates.